Nurix Therapeutics Inc
NASDAQ:NRIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nurix Therapeutics Inc
NASDAQ:NRIX
|
US |
|
Swire Pacific Ltd
HKEX:19
|
HK |
|
Bank Negara Indonesia (Persero) Tbk PT
IDX:BBNI
|
ID |
|
P
|
Power Corporation of Canada
OTC:PWCDF
|
CA |
|
H
|
HP Inc
BMV:HPQ
|
US |
|
D
|
Dollar Tree Inc
F:DT3
|
US |
|
T
|
TriSalus Life Sciences Inc
NASDAQ:TLSI
|
US |
|
Payoneer Global Inc
NASDAQ:PAYO
|
US |
Nurix Therapeutics Inc
Nurix Therapeutics is a drug discovery company focused on targeted protein degradation. It designs medicines that help the cell destroy specific disease-causing proteins instead of just blocking them. Its lead work centers on cancer and immune diseases, where the company is building drug candidates that can act on targets that are hard to reach with standard medicines. Nurix sells value mainly through partnerships with larger drug companies and, if its own drugs succeed, through future product sales. In these collaborations, it can receive upfront payments, research funding, milestone payments, and royalties tied to successful drugs. The main customers for its partnered work are large pharmaceutical companies, while the eventual end users of its medicines are patients and the doctors who treat them. What makes Nurix different is its focus on E3 ligases, the cell machinery that tags proteins for removal. Instead of inventing a drug for one target at a time, it builds a platform for making degrader drugs and for finding new E3 ligase biology that can open up more targets. That gives the company a role both as a research engine for partners and as a developer of its own future medicines.
Nurix Therapeutics is a drug discovery company focused on targeted protein degradation. It designs medicines that help the cell destroy specific disease-causing proteins instead of just blocking them. Its lead work centers on cancer and immune diseases, where the company is building drug candidates that can act on targets that are hard to reach with standard medicines.
Nurix sells value mainly through partnerships with larger drug companies and, if its own drugs succeed, through future product sales. In these collaborations, it can receive upfront payments, research funding, milestone payments, and royalties tied to successful drugs. The main customers for its partnered work are large pharmaceutical companies, while the eventual end users of its medicines are patients and the doctors who treat them.
What makes Nurix different is its focus on E3 ligases, the cell machinery that tags proteins for removal. Instead of inventing a drug for one target at a time, it builds a platform for making degrader drugs and for finding new E3 ligase biology that can open up more targets. That gives the company a role both as a research engine for partners and as a developer of its own future medicines.
